Sibylle Cocciardi

Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with <i>NPM1</i>‐mutated AML

Measurable residual disease monitoring in AML with <i>FLT3</i>-ITD treated with intensive chemotherapy plus midostaurin

Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

The Genomic Landscape and Its Clinical Implication in <i>NPM1</i>-Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Clonal evolution of acute myeloid leukemia with <i>FLT3</i>-ITD mutation under treatment with midostaurin

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication

Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with <i>FLT3</i> Internal Tandem Duplication (<i>FLT3</i>-ITD+ AML) Treated with Additional Midostaurin

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

Abstract 5485: Coactivator PPARGC1B Ala203Pro polymorphism is linked with estrogen-related receptor function and breast cancer outcome

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance